Opendata, web and dolomites

CYTOPRO

Profiling of tumour cells in blood for personalized treatment of metastatic cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CYTOPRO project word cloud

Explore the words cloud of the CYTOPRO project. It provides you a very rough idea of what is the project "CYTOPRO" about.

blood    productivity    losses    tool    lose    isolation    regulatory    individual    personalised    single    prepare    126bn    biased    profile    gt    cytotrack    6bn    fail    medicine    pathologists    primary    42    exact       5bn    markets    approaching    cell    efficient    worth    circulating    gaining    cells    assays    reduce    trials    18    43bn    patient    vasculature    device    ctcs    solution    lost    larger    bloodstream    metastatic    breakthrough    7bn    2009    incl    clinicians    labs    diagnostic    therapy    lives    treatment    isolate    deaths    characterisation    2m    alone    fast    platform    worldwide    10    ctc    foothold    accurate    routine    challenge    perfect    metastasised    superior    customers    days    shed    mutation    cancer    expects    first    12    10bn    form    breast    circulate    patients    market       2013    cheap    technologies    innovation    citizens    40    diagnosed    clinical    detection    tumour    annually   

Project "CYTOPRO" data sheet

The following table provides information about the project.

Coordinator
CYTOTRACK APS 

Organization address
address: GAMMEL LUNDTOFTEVEJ 1D
city: LYNGBY
postcode: 2800
website: www.cytotrack.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.cytotrack.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOTRACK APS DK (LYNGBY) coordinator 50˙000.00

Map

 Project objective

Challenge Up to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.

Solution Circulating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream. CytoTrack has developed a breakthrough technology that can identify and isolate metastatic cancer cells from a blood sample. It is superior to all other technologies due to a very efficient and non-biased detection principle and an integrated feature to isolate individual cells for characterisation. It is the perfect tool to be used together with new single cell characterisation assays currently being introduced on the market.

Impact The innovation will provide an effective, accurate, fast and cheap characterisation of CTCs in a single device, enabling pathologists and clinicians worldwide to deliver personalised medicine and cancer treatment targeted the exact mutation of the individual patient’s cancer form. CytoTrack expects that the innovation can reduce cancer deaths by 10%. In EU alone this would reduce the productivity loss with >€10bn per year and treatment costs with >€12.5bn.

Project This phase 1 project will investigate 1) collaboration with labs, 2) regulatory conditions for first markets, and 3) prepare for clinical trials. The overall innovation project will enable CytoTrack to be the first on the market to offer an integrated diagnostic platform for routine isolation and characterisation of metastatic cancer cells in blood, enabling personalised therapy targeting the exact profile of the cancer form.

Customers and market The CTC technology market was $3.7bn in 2013, growing 18.9% annually. The research market is a first step in gaining a strong foothold before approaching the much larger, but also more challenging, clinical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More